Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Other financing activities (2022 - 2023)

Atara Biotherapeutics' Other financing activities history spans 2 years, with the latest figure at -$13000.0 for Q2 2023.

  • For Q2 2023, Other financing activities changed N/A year-over-year to -$13000.0; the TTM value through Sep 2024 reached -$13000.0, up 74.0%, while the annual FY2025 figure was -$1000.0, 85.71% up from the prior year.
  • Other financing activities reached -$13000.0 in Q2 2023 per ATRA's latest filing, up from -$37000.0 in the prior quarter.
  • In the past five years, Other financing activities ranged from a high of -$13000.0 in Q2 2023 to a low of -$104000.0 in Q1 2022.